Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
22 December 2020 - 9:42AM
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced the appointment of Rick Crowley to the
newly created position of Executive Vice President, Chief
Operations Officer. In this role, Mr. Crowley will have leadership
responsibility for all operations, including Quality,
Manufacturing, Supply Chain and Regulatory Affairs. He takes over
manufacturing from Ben Machielse, who will continue with the
company as an executive advisor to the Chief Executive Officer,
supporting the development of the COVID vaccine.
“Rick’s wealth of biopharmaceutical experience
and record of on-time FDA approvals comes at the perfect time to
help ensure that Novavax delivers on our global manufacturing
mission and supply commitments,” said Stanley C. Erck, Novavax
President and Chief Executive Officer. “We welcome his leadership
as we work to advance not only our COVID-19 candidate, but also
influenza and RSV vaccines.”
Prior to joining Novavax, Mr. Crowley was
Executive Vice President, Technical Operations for TerSera
Pharmaceuticals, where he was responsible for technical support as
well as development and strategy for the company’s products,
created the initial quality systems, and managed all CMC
activities. He served as Senior Vice President, Operations and
Quality Assurance for Crealta Pharmaceuticals 2014-2016, where he
led all aspects of the supply chain function, managed suppliers and
testing, and held responsibility for the management of Regulatory
Affairs. Previously, he held the role of Co-President and Chief
Operating Officer at Savient Pharmaceuticals, with responsibility
for Commercial Operations, Clinical Affairs,
Manufacturing/Technical Operations, Regulatory Affairs, Quality
Assurance, Quality Control, Project Management, Logistics and
Planning. Earlier in his career he held roles of increasing
responsibility at ImClone Systems, Incorporated and BASF
Bioresearch Corp.
“Novavax is well-positioned to execute on a
strategic global operations plan that leverages the company’s
strengths and the expertise of its partners to deliver in the near
and long term,” said Mr. Crowley. “I am impressed with the
astounding progress to-date and look forward to contributing to
continue the momentum.”
Mr. Crowley earned a Bachelor of Science degree
in chemistry from Denison University and a Master of Science in
chemical engineering from the University of Pennsylvania.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The
Company’s proprietary recombinant technology platform combines the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. Novavax is conducting late-stage clinical trials for
NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus
that causes COVID-19. NanoFlu™, its quadrivalent influenza
nanoparticle vaccine, met all primary objectives in its pivotal
Phase 3 clinical trial in older adults and will be advanced for
regulatory submission. Both vaccine candidates incorporate Novavax’
proprietary saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Novavax Forward Looking
Statements
Statements herein relating to the future
of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking
statements. Novavax cautions that these forward-looking
statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include those identified under the heading “Risk
Factors” in the Novavax Annual Report on Form 10-K for the year
ended December 31, 2019, and Quarterly Report on
Form 10-Q for the period ended September 30, 2020,
as filed with the Securities and Exchange
Commission (SEC). We caution investors not to place
considerable reliance on forward-looking statements contained in
this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these
and other risks and uncertainties. The forward-looking statements
in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contacts:InvestorsErika
Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna
Kaplanmedia@novavax.com617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024